How the New Oral GLP-1 Weight Loss Medications Work

A weekly injection is no longer the only way to reap the obesity management and weight loss benefits of glucagon-like peptide-1 (GLP-1) medications. The U.S. Food and Drug Administration (FDA) has approved two oral GLP-1 options: Wegovy (semaglutide) and Foundayo (orforglipron). Both offer a needle-free approach to managing weight and supporting metabolic health.
Learn about how each of those FDA-approved oral weight loss medications work and alternative pill options to consider.
GLP-1 Drugs Affect Your Gut and Brain
These medications also “enhance insulin secretion,” which can result in better blood sugar control in addition to weight loss, says Sara Velayati, MD, an obesity medicine specialist at Montefiore Einstein’s Fleischer Institute Medical Weight Center in New York. By acting on your brain, stomach, and blood sugar systems at the same time, GLP-1 medications can support meaningful weight loss and improve metabolic health over time, she says.
GLP-1s and Your Stomach: The Challenge
The peptide nature of this hormone is why developing effective oral versions of GLP-1 medications has been so challenging, says Dr. Velayati.
Oral Semaglutide
Because the gut is a challenging environment for absorption, oral semaglutide doses are much higher — 25 milligrams (mg) daily — than standard 2.4-mg weekly injections.
Even though the oral dose is higher, only a tiny fraction actually enters the bloodstream. Velayati says your body absorbs only about 0.4 to 1 percent of semaglutide taken by mouth. “So if you take 100 units, less than one actually reaches the bloodstream. But that tiny amount is still enough to have a meaningful clinical effect,” she says. The higher oral dose of semaglutide ensures enough medication survives the stomach acid.
Dosage Timing
If you’re thinking about trying the new weight loss pill instead of the weekly injection, you may need to rethink your morning routine. Unlike the injection, which can be given at any time, the pill requires a strict fasting window. You need to take it on an empty stomach with no more than 4 ounces (oz) of plain water and wait at least 30 minutes before eating breakfast or drinking a cup of coffee.
“The SNAC matrix changes the pH locally where it hits the stomach lining, and this allows absorption,” says W. Timothy Garvey, MD, professor of medicine and director of the University of Alabama at Birmingham’s Diabetes Research Center. “Food prevents this interaction.”
If you eat too soon after taking the pill, food surrounds it in your stomach. That keeps the medication from touching your stomach lining the way it needs to in order to work, says Velayati. Similarly, drinking too much water can dilute the SNAC buffer, and the medication will simply be digested and wasted.
Small-Molecule Drugs
Peptide medications have a large molecular weight and mimic your body’s delicate regulatory signals. “Small molecules are chemically synthesized and designed to interact with receptors and enzymes,” says Dr. Garvey. “They’re smaller in molecular weight than peptide medications that mimic or interfere with endogenous bioregulatory peptides.”
Think of it this way: While a peptide is like a fragile piece of paper that dissolves in the rain, a small molecule is like a tiny pebble, sturdy enough to survive the digestive storm.
Velayati says the natural stability of these newer drugs allows them to survive stomach acid without a special chemical enhancer (like SNAC). Because your body doesn’t try to “digest” these molecules, other drugs in this class, such as Foundayo, likely won’t require strict fasting or perfect timing either.
Resources We Trust
- Mayo Clinic: Pros and Cons of GLP-1 Agonists for Weight Loss
- American Journal of Managed Care: FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
- U.S. Food and Drug Administration: FDA Approves First New Molecular Entity Under National Priority Voucher Program
- Harvard Health Publishing: How Does Ozempic Work? Understanding GLP-1s for Diabetes, Weight Loss, and Beyond
- Obesity Medicine Association: Top Weight Loss Medications
- GLP-1 Agonists. Cleveland Clinic. July 3, 2023.
- Hayashi D et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients. November 17, 2023.
- Collins L et al. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. February 29, 2024.
- FDA Approves Novo Nordisk’s Wegovy Pill, the First and Only Oral GLP-1 for Weight Loss in Adults. PR Newswire. December 22, 2025.
- What Is SNAC in Oral Semaglutide? Biopharma PEG. September 7, 2023.
- FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration. April 1, 2026.
- Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England Journal of Medicine. November 6, 2025.

Sean Hashmi, MD
Medical Reviewer
Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management ...

Susan Jara
Author
Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging conten...